Why the study?
There are currently fewer treatment options for HFmrEF or HFpEF than for heart failure with reduced ejection fraction.
Does finerenone reduce heart failure events or cardiovascular deaths in people with HFmrEF or HFpEF?
Does finerenone reduce heart failure events or cardiovascular deaths in people with HFmrEF or HFpEF?
Answers are grounded in this paper and cite their sources.
Finerenone reduces the risk of heart failure events and cardiovascular death in patients with HFmrEF or HFpEF, though it increases the risk of hyperkalemia.
Plain Language Summary What is this plain language review about? This review describes findings from FINEARTS-HF, a study that assessed finerenone (or KERENDIA®) for treating heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF). In FINEARTS-HF, HFmrEF was defined as an ejection fraction between 40% and 49%, meaning the heart pumps out less blood than usual. HFpEF was defined as an ejection fraction of 50% or more, meaning the heart’s main pumping chamber (the left ventricle) is too stiff and unable to relax properly between beats, which increases pressure inside the heart, causing symptoms of heart failure. What did the researchers want to find out? Researchers investigated whether finerenone (as opposed to placebo) could reduce the chance of heart failure events or deaths from heart-related or blood circulation causes in people with HFmrEF or HFpEF who were already receiving standard heart failure treatment. What were the results? During their time in the study (about 32 months), people who took finerenone were 16% less likely to experience heart failure events or death from heart-related or blood circulation causes than those who took placebo. The results were similar in men and women, people of different ages, people with different medical conditions, and people taking other medications for heart failure. Side effects were mostly similar except that more people taking finerenone (1 in 7) had potassium levels that were too high versus those who took placebo (1 in 14), and more people taking placebo (1 in 10) had potassium levels that were too low versus those who took finerenone (1 in 25). Having potassium levels that are too high or too low can lead to heart rhythm problems, and in severe cases, the heart can suddenly stop beating. There were no deaths in the study due to high or low potassium levels. Potassium-related side effects can be managed with regular monitoring of laboratory potassium levels (part of a structured follow-up plan), changes in diet, and/or changing other medications. What do the results of FINEARTS-HF mean? These results show that finerenone can help stop heart failure from worsening, reduce the risks of hospital or emergency room admissions, and reduce the risk of death in people with HFmrEF or HFpEF. These results are important because there are currently fewer treatment options for HFmrEF or HFpEF than another type of heart failure where ejection fraction is reduced to less than 40% (HFrEF). Clinical trial number: NCT04435626
No takes yet. Share an insight, caveat, or question.
Bains et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: